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Progressive disruption of renal tubular integrity in the setting
of increased cellular proliferation and apoptosis is a feature
of autosomal dominant polycystic kidney disease (ADPKD).
Here we evaluated the effect of these processes on the expres-
sion of Lcn2 (NGAL) and interleukin (IL)-18, markers of tubular
injury, in rodent models and in the cyst fluid and urine of
patients with ADPKD. Two mouse models where Pkd2 was
inactivated, which resulted in early- or adult-onset cysts, were
used to evaluate NGAL levels. Further, the Han:SPRD rat model
of polycystic disease was used to study IL-18 levels. In four
annual serial urine samples collected from 107 patients with
ADPKD in the Consortium for Radiologic Imaging for the
Study of Polycystic Kidney Disease (CRISP) study, NGAL and
IL-18 excretion rates were determined in conjunction with
measures of total kidney volume and estimated glomerular
filtration rate (eGFR) by the Modification of Diet in Renal
Disease equation. Kidneys from affected mice and rats showed
prominent expression of NGAL and IL-18/IL-18R, respectively,
in epithelial cells lining kidney cysts. In human ADPKD cyst
fluid, both NGAL and IL-18 were elevated. In CRISP patients,
the mean percentage increase in total kidney volume was
5.4/year and the mean decline in eGFR 2.4ml/min/year. The
trend of increased mean urine NGAL and IL-18 over 3 years
was statistically significant; however, there was no associa-
tion between tertiles of IL-18 or quartiles of NGAL and
change in total kidney volume or eGFR over this period.
Thus, urinary NGAL and IL-18 excretion is mildly and stably
elevated in ADPKD, but does not correlate with changes in
total kidney volume or kidney function. This may be due, in
part, to the lack of communication between individual cysts
and the urinary collecting system in this disorder.
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Autosomal dominant polycystic kidney disease (ADPKD) is
the most common inherited kidney disease, affecting 1:500 to
1:1000 people, and is the fourth leading cause of end-stage
renal disease in the United States.1 ADPKD is characterized
by massively enlarged kidneys caused by lifelong cyst expan-
sion and is associated with a late decline in kidney function
progressing to renal failure in the majority of patients.2,3 Cyst
growth requires processes of cell proliferation, fluid secretion,
and remodeling of the surrounding milieu. A broad range of
mechanisms have been proposed to underlie these changes,
and the apically located primary cilium, a single hair-like
organelle protruding into the luminal space, has been
implicated as being central to the altered intracellular
signaling processes responsible for increased cellular prolif-
eration and apoptosis.4,5
Specific therapies for ADPKD are lacking,6,7 and one of
the challenges in both clinical care and trial design is the
absence of appropriate biomarkers to monitor disease
progression early in the course of disease before significant
impairment of renal function occurs. Currently, magnetic
resonance imaging-based total kidney volume (TKV) mea-
surements detect early progression. However, magnetic
resonance imaging is expensive, TKV measures are not yet
automated, and structural progression as evidenced by
magnetic resonance imaging may lag behind important intra-
renal functional changes. Importantly, clinical measures
of kidney dysfunction, such as elevated serum creatinine
concentration, occur late in the disease and are inadequate
with regard to identification of worsening cystic disease
measured by TKV in the early stages.8 Therefore, non-
invasive biomarkers developed for diagnostic purposes or
that accurately identify increased renal cyst burden or
increased TKV as well as progressive kidney damage are
important. Identification of such markers could also assist in
identification of patients at increased risk for progression to
end-stage renal disease and could be utilized to determine
the therapeutic benefit of an intervention.
Urine interleukin (IL)-18 and urine NGAL activity are
established biomarkers of acute and chronic kidney injury.9
These are biomarkers of proximal and distal tubular injury
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and ADPKD is a chronic tubulointerstitial disorder. Given
that tubular disruption and cyst formation are key features of
ADPKD, we tested the hypothesis that levels of urinary
NGAL and IL-18 are higher in PKD kidneys and correlate
with increased TKV, decreased kidney function, faster rates of
increase in TKV, and decline in kidney function. In order to
test this hypothesis, we conducted series of preclinical
experiments to establish the presence of IL-18 and NGAL
in PKD models. In addition, urinary IL-18 and NGAL
concentrations were measured in patients from the Consor-
tium for Radiologic Imaging for the Study of Polycystic
Kidney Disease (CRISP) study, where a large cohort of
ADPKD patients with relatively intact kidney function were
studied in a prospective longitudinal manner with regard to
changes in TKV and kidney function or estimated glomerular
filtration rate (eGFR) using the Modification of Diet in Renal
Disease equation.10,11
RESULTS
Preclinical studies
Two orthologous gene mouse models based on Pkd2 inacti-
vation were used to examine NGAL (Lipocalin 2 (Lcn2))
expression in cystic and non-cystic tissues. Adult Pkd2WS25/
mice12 showed strong expression of Lcn2 transcripts detected
by in situ hybridization in cyst-lining cells (Figure 1a–c).
Weaker Lcn2 expression was also present in some pericystic
tubules that appeared otherwise normal (Figure 1a and b).
The second postnatal orthologous gene cystic model
combined a novel transgenic mouse line expressing the
human PKD2 sequence from the pCAGGS vector13
(pCAGGS-PKD2) with the previously described Pkd2/ null
mice that are embryonically lethal.14 Transgenic expression
of PKD2 in Pkd2/;pCAGGS-PKD2 mice partially rescued
the embryonic lethality, cardiac defects, and left–right axis
formation defects observed in Pkd2/ mice14,15 (data not
shown). Surviving mice develop markedly cystic kidneys
during postnatal life (Figure 1d) due to failure of the
transgene to reconstitute expression of PKD2 in kidney
tissues. Immunocytochemical staining of cystic kidneys with
antisera against NGAL16 showed localization of the Lcn2
protein product in the epithelial cells lining the walls of the
majority of cysts in Pkd2/;pCAGGS-PKD2 mice (Figure 1e
and f). A similar pattern of cyst-associated NGAL expression
was found in kidneys from Pkd2WS25/ animals (data not
shown), although there was significant variation in expres-
sion within both models (Figure 1).
IL-18 and IL-18-receptor (IL-18R) expression was exam-
ined in the Han:SPRD (Cy/þ ) cystic rats at 1 year of age.
Cyst-lining epithelial cells showed strong expression of IL-18
(Figure 2a) and IL-18R was expressed in a subset of cells in
regions surrounding the cysts (Figure 2b).
Human cyst fluid
The levels of NGAL and IL-18 in the five pooled cystic fluid
samples are provided in Table 1. Both NGAL and IL-18 levels
are highly elevated compared with both serum and urine
concentrations in normal subjects or in patients with acute
kidney injury.17,18
Longitudinal patient studies
Urine samples were available at baseline in 209 of 241 CRISP
participants. The mean age of these CRISP participants was
32.1 years and 41.2% were male. The baseline mean eGFR
was 89.39ml/min per 1.73m2 and the mean TKV was
1080ml range (308–3196ml). Urine samples were available
for 156 participants at year 1, for 133 at year 2, and for 211 at
year 3. Urine samples were collected from 107 patients at
baseline and all three follow-up visits.
The urinary NGAL and IL-18 raw concentration levels
at baseline and follow-up visits are given in Figure 3. The
majority of patients demonstrated levels considered to be
within the normal range or low at baseline, with approxi-
mately 35% and 16% of patients with levels 420U/ml for
NGAL and IL-18, respectively. Only 7% and 2% of patients
had levels of NGAL and IL-18, respectively, 4100U/ml,
similar to the levels seen in patients with acute kidney injury.17–20
Table 2 demonstrates that among those with biomarker
data at every visit, the corrected and uncorrected biomarker
levels change over 3 years. Tests for a linear and quadratic
trend over 3 years in both biomarker levels (corrected and
uncorrected) were statistically significant (Pp0.05), implying
an initial increase in the levels, which then dropped in years
2 and 3.
Biomarkers and outcomes. Baseline tertiles for biomarker
concentrations and biomarkers corrected for creatinine
concentrations of IL-18 and quartiles for NGAL were not
associated with percent change in TKV or change in eGFR at
3 years of follow-up (Tables 3a and 3b). No associations were
found between baseline TKV and eGFR or change in TKV or
eGFR over time when grouped by detectable versus not
detectable limits (X10 pg/ml for IL-18 and X1 ng/ml for
NGAL; data not shown).
DISCUSSION
In our series of preclinical and clinical studies we demon-
strated that NGAL and IL-18 are present and highly
expressed in the epithelial cells lining kidney cysts. We also
found that urinary NGAL and IL-18 excretion were mildly
and constantly elevated in ADPKD and change over time, but
did not correlate with worsening in kidney function or
increase in TKV. The discrepant findings between cyst
epithelial expression and fluid versus urinary excretion of
these biomarkers are possibly due to the lack of commu-
nication between the cystic space and the urinary collecting
system. It is well known that renal cysts in ADPKD kidneys
detach from the parent nephron soon after reaching 2 cm in
diameter. Some patients had very high levels in the urine,
which may be related to acute fluctuations in these cyto-
kines that occur during periods of rapid cyst expansion. As
such, annual measurements in TKV may not be sufficiently
sensitive to detect changes associated with acute cyst
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expansion. Also, eGFR in the majority of these ADPKD
patients remained stable, consistent with the natural history
of this disorder. Typically cyst expansion is relatively slow,
with detectable changes in size limited to 6 months in most
ADPKD patients.21 Capturing patients with acute rapid rates
of cyst expansion (i.e., during acute cyst hemorrhage) may
demonstrate the usefulness of these markers.
NGAL expression increases in renal epithelial cells in
response to injury.22 Increases in urinary NGAL levels have
been found to be predictive of acute kidney injury in patients
undergoing cardiac surgery and in other hospitalized
settings.9,18 NGAL gene expression is also increased in
human ADPKD-derived cell lines and tissue,23 in the
HAN:SPRD (cy/þ ) rat model of ADPKD,24 and in the cpk
mouse model of recessive PKD.25 Thus, NGAL emerged as a
potentially interesting biomarker of progression in ADPKD.
In the present study, NGAL (Lcn2) was found to be highly
expressed in two distinct orthologous mouse models of
ADPKD. This increased expression is seen at both the mRNA
and protein level and is associated with the cells lining the
cysts in these mouse models.
Urinary IL-18 is elevated during apoptosis and necrosis of
renal tubular cells, which is associated with acute kidney
a
d e f
b c
Figure 1 | Expression of Lcn2 (NGAL) in orthologous gene mouse models of polycystic kidney disease. (a–c) RNA in situ hybridization
for Lcn2 in a Pkd2WS25/ cystic kidney showing expression (dark reactivity) after hybridization with the Lcn2-specific antisense RNA probe
(a, b) in epithelial cyst-lining cells and in some pericystic tubules; (c) the sense probe lacks reactivity. The boxed area in panel a is
shown in higher magnification in panel b (inset is digitally enlarged). (d) The appearance of kidneys from Pkd2/;pCAGGS-PKD2 mice
at postnatal day 10. (e, f) Immunocytochemistry showing expression of NGAL in cyst-lining epithelia of Pkd2/;pCAGGS-PKD2 mice (NGAL,
green; a-tubulin, red; 4’,6-diamidino-2-phenylindole, blue. Original magnifications: (a, c)  10; (b)  40; (e, f)  20.
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Figure 2 | Interleukin (IL)-18 expression in Han:SPRD (Cy/þ ) rats. (a) Immunocytochemistry showing strong expression of IL-18
(green) in cells lining the cysts in 1-year-old Han:SPRD (Cy/þ ) rats. (b) IL-18 receptor expression (red) is also observed in cells adjacent to
some cysts. Staining is also seen in the nucleus and interstitium. 4’,6-diamidino-2-phenylindole, blue. Original magnification,  400.
Table 1 | NGAL and IL-18 concentrations in the cyst fluid
obtained during nephrectomy in PKD patients
Kidney status at
nephrectomy Age Gender
NGAL
(ng/ml)a
IL-18
(pg/ml)a
SCr: 1.7; prior
transplant; no dialysis
60 M 140 100
SCr: 8.5; dialysis 54 F 4939 380
SCr: 4.4; dialysis 46 F 979 152
SCr: 5.1; prior
transplant; no dialysis
54 M 449 309
SCr: NA; no dialysis; ESRD 49 F 3625 588
Abbreviations: ESRD, end-stage renal disease; IL-18, interleukin-18; NA, not
applicable; SCr, serum creatinine.
aUrinary levels of IL-18 and NGAL are usually o25 pg/ml and o20 ng/ml,
respectively in healthy adults.
786 Kidney International (2012) 81, 784–790
or ig ina l a r t i c l e CR Parikh et al.: Urine biomarkers of kidney injury
injury in rodent and human studies.26,27 Given that apoptosis
contributes to the pathogenesis of cyst formation in
ADPKD,28 we measured IL-18 and its receptor levels in
murine and human renal cysts. IL-18 expression was
prominent in the cystic epithelial cells in kidneys of 1-year-
old Han:SPRD (Cy/þ ) rats. As IL-18 signals via the IL-18R,
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Figure 3 |Biomarker distribution in the Consortium for Radiologic Imaging for the Study of Polycystic Kidney Disease cohort at
each visit. Raw values of (a) interleukin-18 values are in pg/ml and (b) NGAL values are in ng/ml.
Table 2 | Biomarker values over time for 107 participants who followed up for all visits
Baseline visit 1-year follow-up 2-year follow-up 3-year follow-up
Mean s.d. Median Mean s.d. Median Mean s.d. Median Mean s.d. Median
Variable
Urine IL-18 (ng/ml)a 13.8 26.7 1.0 23.5 58.2 1.0 9.3 24.0 1.0 8.4 19.5 1.0
Urine NGAL (pg/ml)a 32.3 52.7 14.3 43.2 86.7 11.3 20.2 42.9 6.2 19.5 29.5 10.6
Urine creatinine (mg/ml) 0.9 0.7 0.8 1.0 0.6 1.0 0.8 0.6 0.7 1.0 0.6 0.9
NGAL/creatinine (ng/mg)a 37.6 51.2 16.1 40.0 64.9 11.4 27.4 37.4 13.4 22.9 34.3 10.3
IL-18/creatinine (pg/mg)a 13.0 18.8 5.3 19.7 42.4 3.2 8.4 12.5 3.4 7.2 13.1 1.9
Abbreviation: IL-18, interleukin-18.
aPp0.05 for linear and quadratic trend and Friedman’s chi-squared test.
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the expression of IL-18R in the epithelial cells lining the cysts
suggests that IL-18 may be having a biological effect during
cyst formation or expansion. IL-18 and NGAL levels are also
highly enriched in cyst fluid derived from ADPKD patients,
demonstrating translation of the findings from murine and
rat models to human disease. This prompted us to evaluate
whether IL-18 and NGAL had clinical utility as biomarkers
for progression of ADPKD using samples from the CRISP
cohort.
The results of the current study are in contrast to the
results from Bolignano et al.,29 in which 26 patients with
ADPKD were evaluated by serum and urinary measurements
of NGAL. Urinary and serum NGAL levels were higher in
patients with ADPKD compared with controls, and propor-
tionately higher in those patients with advanced disease.
However, the patients with ADPKD already had a substantial
reduction in renal function with a mean creatinine clearance
of 59±38ml/min, which is far lower than the value
obtained for the CRISP population studied here and lower
than that obtained for the control group (115±32ml/min).
It is possible that the elevations in serum and urinary
NGAL concentrations found in this study were related more
to the level of renal dysfunction than to the presence of
renal cystic disease. Thus, NGAL may have utility as a
biomarker during later stages of ADPKD in the event of a
decline in glomerular filtration rate associated with advanced
ADPKD disease.
Although we conducted a systematic evaluation of the
kidney injury biomarkers in both pre-clinical and clinical
settings of ADPKD, there are few limitations to consider.
NGAL and IL-18 are relatively stable through multiple
freeze–thaw cycles and the levels are known to be stable for at
least 3 years at 80 1C. In addition, we have found predict-
able results with these biomarkers in other studies where
samples were collected and stored for several years, so it is
likely that these biomarkers were stable in PKD urine
samples.19 Although the samples were handled uniformly
across the study visits, the reasons for the fall in the
biomarker levels during the follow-up period were unclear.
Other potential biomarkers for progression in ADPKD
include monocyte chemoattractant protein-1,30 B-N-acetyl-
hexosaminidase,31 and KIM-1.32 Kistler et al.33 found that a
unique urinary proteomic profile and pathway could
correctly identify patients with ADPKD. It is possible that a
combination of urinary biomarkers as opposed to a single
biomarker could predict disease progression better in PKD.
MATERIALS AND METHODS
Preclinical studies
Animals and tissue samples. Three mouse strains based on
Pkd2 inactivation and one rat model of autosomal dominant
Table 3a |Mean annual % change in total kidney volume and
eGFR at 1 year and 3 years from baseline by IL-18 tertile
1-year % TKV change
Baseline IL-18 tertile N Mean s.d.
p1 127 4.12 6.61
41 and o19 37 4.95 7.83
X19 and p434 39 5.66 5.66
3-year % TKV change
Baseline IL-18 tertile N Mean s.d.
p1 126 16.40 14.17
41 and o19 37 19.93 16.54
X19 and p434 38 17.11 12.65
1-year % eGFR change
Baseline IL-18 tertile N Mean s.d.
p1 127 2.57 15.86
41 and o19 37 0.55 12.68
X19 and p434 39 7.13 13.16
3-year % eGFR change
Baseline IL-18 tertile N Mean s.d.
p1 127 8.16 18.23
41 and o19 37 5.76 14.39
X19 and p434 38 12.25 17.12
Abbreviations: eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; TKV,
total kidney volume.
No significant differences by baseline IL-18 tertile for TKV or eGFR changes.
Table 3b |Mean annual % change in total kidney volume and
eGFR at 1 year and 3 years from baseline by NGAL quartile
1-year % TKV change
Baseline NGAL quartile N Mean s.d.
o3.65 51 5.24 7.69
X3.65 and o11.5 48 4.43 6.42
X11.5 and o31.6 53 3.38 6.73
X31.6 and p315.62 51 5.26 5.73
3-year % TKV change
Baseline NGAL quartile N Mean s.d.
o3.65 50 18.98 14.80
X3.65 and o11.5 50 17.20 13.70
X11.5 and o31.6 51 15.42 15.10
X31.6 and p315.62 50 17.15 13.99
1-year % eGFR change
Baseline NGAL quartile N Mean s.d.
o3.65 51 1.93 15.27
X3.65 and o11.5 48 1.98 15.87
X11.5 and o31.6 53 7.23 14.81
X31.6 and p315.62 51 0.94 13.27
3-year % eGFR change
Baseline NGAL quartile N Mean s.d.
o3.65 51 5.83 17.30
X3.65 and o11.5 50 9.10 17.00
X11.5 and o31.6 51 12.59 17.79
X31.6 and p315.62 50 6.42 17.25
Abbreviations: eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; TKV,
total kidney volume.
No significant differences by baseline NGAL quartile for TKV or eGFR changes.
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proximal cystic disease were used. NGAL experiments utilized the
mouse strains Pkd2WS2512 and Pkd2WS183 (null allele, a.k.a., Pkd2)14
and a novel transgenic mouse line expressing the human PKD2
sequence from the pCAGGS vector13 (pCAGGS-PKD2). Cystic
kidneys were obtained from 8-weeks-old Pkd2WS25/ mice and 10-
day-old Pkd2/;pCAGGS-PKD2 mice. One year old polycystic
Han:SPRD (Cy/þ ) rats were used for IL-18 studies.34
RNA in situ hybridization. For in situ hybridization, serial
cryostat sections (4–5 mm) of snap-frozen kidneys were mounted on
aminopropylsilane-coated slides and fixed with 4% paraformalde-
hyde. After acetylation, the slides were prehybridized at 42 1C in
45% formamide, 0.6mol/l NaCl, 2.5 Denhardt’s solution,
10mmol/l Tris-HCl, 1mmol/l EDTA, 0.1% SDS, and 0.15mg/ml
transfer RNA. Digoxigenin-labeled Lcn2-specific anti-sense (and
sense control) riboprobes were generated by in vitro transcription
and hybridized to the sections dissolved in pre-hybridization
solution containing an additional 10% dextran sulfate at 42 1C for
16 h. The slides were then washed in 50% formamide/1 standard
sodium citrate at 55 1C treated with RNAse, and washed twice in
0.1 standard sodium citrate at room temperature. Signal was
detected by an antibody reaction to digoxigenin according to the
manufacturer’s protocol (Roche, Nutley, NJ). Sections were lightly
counterstained with hematoxylin and photographed using a Nikon
TE2000U microscope (Nikon, Tokyo, Japan).
Immunocytochemistry. Kidneys were obtained from anesthe-
tized mice by perfusion fixation with 0.4% lidocaine and 0.01%
heparin followed by 4% paraformaldehyde in phosphate-buffered
saline. Sections 4–5 mm thick were blocked with 0.1% bovine serum
albumin/10% goat serum in phosphate-buffered saline for 1 h at
room temperature and incubated with primary antibodies overnight
at 4 1C followed by the secondary antibodies for 1 h at room
temperature. Images were obtained with a Nikon TE2000U inverted
microscope. The polyclonal antibody to lipocalin-2 was a kind gift
from Jonathan Barasch (Columbia University, New York) and was
applied at a dilution of 1:500.16 Anti-a-tubulin antibody was
obtained from Sigma (St Louis, MO). Secondary antibodies were
conjugated with Cy5 or Cy3.
For immunofluorescence of rat samples, kidney tissues were
embedded in Tissue-Tek OCT Compound (Sakura, Alphen aan den
Rijn, The Netherlands), snap-frozen in liquid nitrogen, and stored at
80 1C. Cryostat sections (5 mm) were fixed in 70% acetone/30%
methanol and prepared for immunofluorescence studies as pre-
viously described.31 A rabbit polyclonal IL-18 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, catalogue number sc-7954) anti-
body was used.
Clinical studies
Human kidney cyst samples. Samples of cyst fluid were
collected from several cysts and pooled in each of five ADPKD
nephrectomy specimens. All participants had established renal
insufficiency or were receiving renal replacement therapy. The
indications for nephrectomy in these patients were symptoms
including pain, shortness of breath, early satiety, increases in
abdominal girth, or as a requirement in preparation for renal
transplantation. Cyst fluid was obtained at the time of surgery and
aliquoted and stored at 20 1C immediately.
CRISP cohort: longitudinal studies of human ADPKD. These
protocols were reviewed by the CRISP Ancillary Studies committee
and were approved by the CRISP Steering committee and the
Yale Institutional Review Board. The CRISP Consortium is an
NIH-funded UO1 cooperative agreement that began in 2000.
Two hundred and forty one ADPKD participants with relatively
intact kidney function (creatinine clearance470ml/min) with two-
thirds at increased risk for progression to renal failure were enrolled.
Participants were studied on an annual basis in a standardized
fashion as reported elsewhere.11 Urine samples were obtained from
CRISP participants in the fasting state as a first void at baseline and
at each annual visit for 3 consecutive years. The samples were
handled uniformly across enrolling sites as per the study protocol.
The urine samples were centrifuged immediately after collection; the
supernatant was separated, aliquoted, and frozen at 80 1C until
assays were performed. No protease inhibitors or other additives
were added to the urine samples after collection. Samples underwent
one freeze–thaw cycle before biomarker measurement.
Biomarker assays. Specimens were randomly ordered for
biochemical analysis, and the personnel performing the biochemical
assays were blinded to clinical information and subject identifica-
tion. The urine NGAL enzyme-linked immunosorbent assay was
performed as described previously for urine and cyst fluid.18 Briefly,
microtiter plates precoated with a mouse monoclonal antibody
raised against human NGAL (HYB211-05, AntibodyShop, Gentofte,
Denmark) were blocked with buffer containing 1% bovine serum
albumin, coated with 100 ml of patient samples, and incubated with
a biotinylated monoclonal antibody against human NGAL
(HYB211-01B, AntibodyShop) followed by addition of avidin-
conjugated HRP (Dako, Carpinteria, CA). Tetramethylbenzidine
substrate (BD Biosciences, San Jose, CA) was added for color
development, which was read after 30min at 450 nm with a
microplate reader (Benchmark Plus, BioRad, Hercules, CA). The
inter- and intra-assay coefficient variations were 5% and 10%,
respectively, for samples analyzed on the same day. Urine creatinine
was measured using a quantitative colorimetric assay kit (Sigma).
IL-18 was measured in human urine and cyst fluid using a human
IL-18 ELISA kit (Medical and Biologic Laboratories, Nagoya, Japan)
that specifically detects the mature form of IL-18 as described
previously.17 The coefficients of variation of inter- and intra-assay
reproducibility for IL-18 concentration were 7% and 10%,
respectively. Measurements of IL-18 and NGAL concentrations were
repeated on 10% of randomly chosen samples to confirm the
reliability of the measurement.
Statistical analysis
The data were examined using SAS system software (SAS Institute,
Cary, NC). Although 241 ADPKD patients were enrolled in CRISP,
not every participant completed all 3 years of study, and in select
individuals urine samples were either not available or the participant
was pregnant and the urine sample was not appropriate for use.
When comparing levels over time within individuals, we restricted
the sample to the 107 patients who had results available at every visit.
Urine NGAL and IL-18 biomarker levels were measured at each
study visit. TKV was measured using magnetic resonance imaging,
details of which are provided in the CRISP protocol, and the
Modification of Diet in Renal Disease formula was used to estimate
eGFR. To assess change in TKV and eGFR, we calculated the percent
change at each year from baseline. To test for a linear or quadratic
trend, a general linear model with repeated measures was used and
the results were supplemented with Friedman’s test owing to the
skewed distribution of the data. Baseline urine biomarkers were
grouped by quartile for NGAL and by tertile for IL-18. Analysis of
variance was used to test for differences in TKV and Modification of
Diet in Renal Disease glomerular filtration rate by IL-18 tertiles and
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NGAL quartiles. As seen below, IL-18 concentrations were undetectable
in over 50% of participants. To address data inclusion for all subjects,
all raw IL-18 values were increased by 1 to avoid zero values.
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